Unknown

Dataset Information

0

Radium 223 dichloride for prostate cancer treatment.


ABSTRACT: Prostate cancer is the most common malignant disease in men. Several therapeutic agents have been approved during the last 10 years. Among them, radium-223 dichloride (Xofigo®) is a radioactive isotope that induces irreversible DNA double-strand breaks and consequently tumor cell death. Radium-223 dichloride is a calcium-mimetic agent that specifically targets bone lesions. Radium-223 dichloride has been approved for the treatment of metastatic castration-resistant prostate cancer with symptomatic bone metastases, without known visceral metastases. In this review, first we summarize the interplay between prostate tumor cells and bone microenvironment; then, we discuss radium-223 dichloride mechanism of action and present the results of the available clinical trials and future developments for this new drug.

SUBMITTER: Deshayes E 

PROVIDER: S-EPMC5593411 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature

altmetric image

Publications


Prostate cancer is the most common malignant disease in men. Several therapeutic agents have been approved during the last 10 years. Among them, radium-223 dichloride (Xofigo<sup>®</sup>) is a radioactive isotope that induces irreversible DNA double-strand breaks and consequently tumor cell death. Radium-223 dichloride is a calcium-mimetic agent that specifically targets bone lesions. Radium-223 dichloride has been approved for the treatment of metastatic castration-resistant prostate cancer wit  ...[more]

Similar Datasets

| S-EPMC4467240 | biostudies-other
| S-EPMC5071661 | biostudies-literature
| S-EPMC4654149 | biostudies-other
| S-EPMC5809574 | biostudies-literature
| S-EPMC6572036 | biostudies-literature
| S-EPMC4445785 | biostudies-literature
| S-EPMC4492702 | biostudies-literature
| S-EPMC5608784 | biostudies-literature
| S-EPMC5537325 | biostudies-other
| S-EPMC4961730 | biostudies-literature